Global T-Cell Lymphoma Pipeline Market Report 2021 - ResearchAndMarkets.com

The "T Cell Lymphoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "T cell lymphoma - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

T cell lymphoma Emerging Drugs Chapters

This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

T cell lymphoma Emerging Drugs

SGX-301: Soligenix

SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known - it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.

Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.

SP-02: Solasia Pharma

SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.

It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.

Major Players working on T cell lymphoma

There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.

T cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.

Current Scenario and Emerging Therapies:

• How many companies are developing T cell lymphoma drugs?
• How many T cell lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for T cell lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Celgene
• CSPC ZhongQi Pharmaceutical Technology
• Jazz Pharmaceuticals
• Genor Biopharma
• Eisai
• Soligenix
• Elorac
• Shanghai YingLi Pharmaceutical
• ViGenCell
• Daiichi Sankyo
• Chia Tai Tianqing Pharmaceutical Group
• BeiGene
• Kura Oncology
• Solasia Pharma
• Innovent bilogics
• Nanjing Sanhome Pharmaceutical
• Rhizen Pharmaceuticals SA
• 4SC AG
• Precision Bioscience
• Millennium Pharmaceuticals, Inc.
• Innate Pharma
• ImmuneOncia Therapeutics
• HUYA Bioscience International
• CerRx, Inc.
• Shandong New Time Pharmaceutical Co., LTD
• Verastem, Inc.
• Janssen Research & Development
• Celleron Therapeutics
• CStone Pharmaceuticals
• Viridian Therapeutics
• Hebei Senlang Biotechnology Inc.
• Galderma
• Seagen
• Bioniz Therapeutics
• Almirall
• Dizal Pharmaceuticals
• Pfizer
• Hoffmann-La Roche
• Affimed GmbH
• Sorrento Therapeutics
• Merck Sharp & Dohme
• Eli Lilly and Company
• Bayer
• Genzyme
• Portola Pharmaceuticals
• Onyx Pharmaceuticals
• AstraZeneca
• Astex Therapeutics
• Yake Biotechnology Ltd.
• Aileron Therapeutics
• Akeso Pharmaceuticals, Inc.
• Viracta
• Otsuka Pharmaceutical
• VelosBio
• Trillium Therapeutics Inc.
• Mundipharma-EDO GmbH
• TG Therapeutics, Inc.
• PersonGen BioTherapeutics (Suzhou) Co
• Sorrento Therapeutics
• Oncotartis
• Myeloid Therapeutics
• Bio-Path Holdings, Inc.
• Legend Biotech
• Immune Cell
• Genzada Pharmaceuticals
• Gracell
• CRISPR Therapeutics
• Corvus Pharmaceuticals, Inc.
• Rafael Therapeutics
• Antengene Corporation
• Viridian Therapeutics
• iCell Gene Therapeutics
• Tessa Therapeutics
• Boryung Pharmaceutical Co., Ltd
• Bristol-Myers Squibb
• Antengene Corporation
• Amgen
• ADC Therapeutics S.A.
• Legend Biotech USA Inc
• VidacPharma
• Medc Biopharma
• Scopus Biopharma
• Almirall
• Brickell Bio
• AVM Biotechnology
• Autolus
• Applied Therapeutics
• TetraLogic Pharmaceuticals
• Moleculin Biotech

Key Products

• Lenalidomide
• Mitoxantrone Hydrochloride
• JZP-458
• GB226
• Denileukin diftitox
• SGX 301
• Naloxone Hydrochloride
• YY-20394
• VT-EBV-N
• Valemetostat Tosylate
• TQ-B3525
• TQ-B3101
• Tislelizumab
• Tipifarnib
• SP-02L
• SP-02
• Sintilimab
• SHC014748M
• SGN-35
• RP6530
• Resminostat
• Pembrolizumab
• PBCAR20
• Nivolumab
• MLN 9708
• Letermovir
• Lacutamab
• IPH4102
• IMC-001
• HBI-8000
• Fenretinide
• F520
• Duvelisib
• DS-3201
• Daratumumab
• CXD 101
• CS1001
• Cobomarsen
• CD7 CAR-T
• CD11301
• Brentuximab Vedotin
• BNZ132-1-40
• BNZ1
• AZD4205
• Azacytidine
• Avelumab
• Atezolizumab
• AFM13
• STI-3031
• MK-3475
• LY3039478
• Durvalumab
• Copanlisib
• Clofarabine
• Cerdulatinib (PRT062070)
• carfilzomib
• AZD5991
• ASTX660
• ALRN-6924
• AUTO4
• AK104
• Nanatinostat + Valganciclovir
• ASTX660
• ARGX-110
• VLS-101
• TTI-621
• Tinostamustine
• TGR-1202
• Temsirolimus
• Sofusa anti-PD1
• SEA-TGT
• OT-82
• MT-101
• L-Bcl-2 antisense oligonucleotide
• LB1901
• ICAR30 T cells
• GZ17-6.02
• GC027
• CTX130
• CPI-818
• CPI-613/Devimistat
• Cobomarsen
• CD4 CAR T cells
• CD30.CAR-T
• BR101801
• BMS-906024
• AZD4573
• ATG-010
• AMG 319
• ADCT-301
• LB1901
• CD7-CART
• VDA-1102
• MDC 2021
• MDC 2020
• CO-sTiRNA
• CD-7 UCART
• BNZ1
• BBI-3000
• AVM-0703
• Auto 5
• AT-104
• Lorlatinib
• CPX-351
• SHP-141
• WP1220

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o2ri8e

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005573/en/